Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D S Cross

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Radiologic Technology|April 29, 1998
How to make active learning work for youB G Tanenbaum, D S Cross, E R Tilson, et al.
Radiologic Technology|August 8, 1998
Health professionals as patient educatorsD S Cross, A T Rodgers, E R Tilson, et al.
Acta Oto-Laryngologica. Supplementum|January 1, 1992
The levels of IL-1 beta in human middle ear effusionsS K Juhn, C T Tolan, W J Garvis, et al.
Cancer Research|April 15, 1987
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bileG D Heggie, J P Sommadossi, D S Cross, et al.
Advances in Experimental Medicine and Biology|January 1, 1997
Tumor infiltrating lymphocytes in squamous cell carcinoma of the head and neck: mechanisms of enhancement using prostaglandin synthetase inhibitorsD S Cross, J L Platt, S K Juhn, et al.
Archives of Otolaryngology--Head & Neck Surgery|May 1, 1992
Administration of a prostaglandin synthetase inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neckD S Cross, J L Platt, S K Juhn, et al.
Cancer Research|January 1, 1985
Modulation of 5-fluorouracil catabolism in isolated rat hepatocytes with enhancement of 5-fluorouracil glucuronide formationJ P Sommadossi, D A Gewirtz, D S Cross, et al.
Cancer Research|June 1, 1985
Evidence from rat hepatocytes of an unrecognized pathway of 5-fluorouracil metabolism with the formation of a glucuronide derivativeJ P Sommadossi, D S Cross, D A Gewirtz, et al.
Current Medical Research and Opinion|October 25, 2012
Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohortsD S Cross, C A McCarty, E Hytopoulos, et al.
Physical Review Letters|March 17, 2011
High-precision half-life measurement for the superallowed β+ emitter ²⁶Al(m)P Finlay, S Ettenauer, G C Ball, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Radiologic Technology|April 29, 1998
How to make active learning work for youB G Tanenbaum, D S Cross, E R Tilson, et al.
Radiologic Technology|August 8, 1998
Health professionals as patient educatorsD S Cross, A T Rodgers, E R Tilson, et al.
Acta Oto-Laryngologica. Supplementum|January 1, 1992
The levels of IL-1 beta in human middle ear effusionsS K Juhn, C T Tolan, W J Garvis, et al.
Cancer Research|April 15, 1987
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bileG D Heggie, J P Sommadossi, D S Cross, et al.
Advances in Experimental Medicine and Biology|January 1, 1997
Tumor infiltrating lymphocytes in squamous cell carcinoma of the head and neck: mechanisms of enhancement using prostaglandin synthetase inhibitorsD S Cross, J L Platt, S K Juhn, et al.
Archives of Otolaryngology--Head & Neck Surgery|May 1, 1992
Administration of a prostaglandin synthetase inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neckD S Cross, J L Platt, S K Juhn, et al.
Cancer Research|January 1, 1985
Modulation of 5-fluorouracil catabolism in isolated rat hepatocytes with enhancement of 5-fluorouracil glucuronide formationJ P Sommadossi, D A Gewirtz, D S Cross, et al.
Cancer Research|June 1, 1985
Evidence from rat hepatocytes of an unrecognized pathway of 5-fluorouracil metabolism with the formation of a glucuronide derivativeJ P Sommadossi, D S Cross, D A Gewirtz, et al.
Current Medical Research and Opinion|October 25, 2012
Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohortsD S Cross, C A McCarty, E Hytopoulos, et al.
Physical Review Letters|March 17, 2011
High-precision half-life measurement for the superallowed β+ emitter ²⁶Al(m)P Finlay, S Ettenauer, G C Ball, et al.
Pageof 3